Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR Most-commonly tested cancer biomarkers using NGS in Europe… Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)
Larger gene panels are the predominant NGS testing strategy in EU5 Larger gene panels are the predominant NGS testing strategy… Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)
Europe: precision medicine and access to NGS cancer biomarker testing Precision medicine and access to NGS cancer biomarker… Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)
Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019 Proportion of cancer biomarker testing done with NGS… Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)
Watch on-demand: Will Covid-19 Accelerate the Next Wave of Adoption of Next-Generation Sequencing (NGS) in Healthcare? Now, sequencing looks set to become even more integral in… Uncategorised | Global | IVD Gateway | Sequencing
The fastest-growing areas for LATAM’s next-generation sequencing market The next-generation sequencing (NGS) market is expected to… Healthcare | Americas | IVD Gateway | Sequencing
The fastest-growing areas for APAC’s next-generation sequencing market The next-generation sequencing (NGS) market is expected to… Healthcare | Asia | IVD Gateway | Sequencing
2022 healthcare megatrends shaping IVD 2022 healthcare megatrends shaping IVD… Healthcare | Asia | Europe | Middle East & Africa | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Sequencing
Keeping ahead of infectious diseases in Asia-Pacific with increased testing Our new briefing paper looks at the testing trends in… Healthcare | Asia | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Sequencing